These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37630633)

  • 1. Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.
    Tsiakalos A; Ziakas PD; Polyzou E; Schinas G; Akinosoglou K
    Microorganisms; 2023 Aug; 11(8):. PubMed ID: 37630633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
    Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
    JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.
    Wannigama DL; Hurst C; Phattharapornjaroen P; Hongsing P; Sirichumroonwit N; Chanpiwat K; Rad S M AH; Storer RJ; Ounjai P; Kanthawee P; Ngamwongsatit N; Kupwiwat R; Kupwiwat C; Brimson JM; Devanga Ragupathi NK; Charuluxananan S; Leelahavanichkul A; Kanjanabuch T; Higgins PG; Badavath VN; Amarasiri M; Verhasselt V; Kicic A; Chatsuwan T; Pirzada K; Jalali F; Reiersen AM; Abe S; Ishikawa H;
    EClinicalMedicine; 2024 Apr; 70():102517. PubMed ID: 38516100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial.
    Reiersen AM; Mattar C; Bender Ignacio RA; Boulware DR; Lee TC; Hess R; Lankowski AJ; McDonald EG; Miller JP; Powderly WG; Pullen MF; Rado JT; Rich MW; Schiffer JT; Schweiger J; Spivak AM; Stevens A; Vigod SN; Agarwal P; Yang L; Yingling M; Gettinger TR; Zorumski CF; Lenze EJ
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad419. PubMed ID: 37622035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
    Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
    Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
    Deng J; Rayner D; Ramaraju HB; Abbas U; Garcia C; Heybati K; Zhou F; Huang E; Park YJ; Moskalyk M
    Clin Microbiol Infect; 2023 May; 29(5):578-586. PubMed ID: 36657488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial.
    Seo H; Kim H; Bae S; Park S; Chung H; Sung HS; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Son KY; Chong YP
    Infect Chemother; 2022 Mar; 54(1):102-113. PubMed ID: 35384422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
    Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
    Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
    Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.
    Farahani RH; Ajam A; Naeini AR
    BMC Infect Dis; 2023 Mar; 23(1):197. PubMed ID: 37003990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
    Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
    JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study.
    Pineda E; Singh J; Pineda MV; Umanzor JG; Baires F; Benitez LG; Burgos C; Sekhon AK; Crisp N; Lewis AS; Radwanski J; Bermudez M; Barjun KS; Diaz O; Palou E; Escalante RE; Hernandez CI; Stevens ML; Eberhard D; Sierra M; Alvarado T; Videa O; Sierra-Hoffman M; Valerio-Pascua F
    Front Pharmacol; 2022; 13():1054644. PubMed ID: 36532727
    [No Abstract]   [Full Text] [Related]  

  • 13. An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment.
    Arishi NA; Althomali NM; Dighriri IM; Alharthi MS; Alqurashi GB; Musharraf RA; Albuhayri AH; Almalki MK; Alnami SA; Mashraqi ZO
    Cureus; 2023 Jan; 15(1):e34158. PubMed ID: 36843775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.
    Vatvani AD; Kurniawan A; Hariyanto TI
    Ann Pharmacother; 2023 Dec; 57(12):1389-1397. PubMed ID: 37002592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
    Reis G; Dos Santos Moreira Silva EA; Medeiros Silva DC; Thabane L; de Souza Campos VH; Ferreira TS; Quirino Dos Santos CV; Ribeiro Nogueira AM; Figueiredo Guimaraes Almeida AP; Cançado Monteiro Savassi L; de Figueiredo Neto AD; Bitarães C; Cruz Milagres A; Diniz Callegari E; Campos Simplicio MI; Barra Ribeiro L; Oliveira R; Harari O; Wilson LA; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Guyatt GH; Rayner CR; Boulware DR; Ezer N; Lee TC; McDonald EG; Bafadhel M; Butler C; Rodrigues Silva J; Dybul M; Mills EJ;
    Ann Intern Med; 2023 May; 176(5):667-675. PubMed ID: 37068273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study.
    Trkulja V; Kodvanj I
    Eur J Clin Pharmacol; 2023 May; 79(5):643-655. PubMed ID: 36961578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.
    Calusic M; Marcec R; Luksa L; Jurkovic I; Kovac N; Mihaljevic S; Likic R
    Br J Clin Pharmacol; 2022 May; 88(5):2065-2073. PubMed ID: 34719789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
    Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Tu YK; Yang SN; Hsu TW; Yeh TC; Liang CS
    Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36901099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.